Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential

Sclerostin expression in the subchondral bone of patients with knee osteoarthritis

(2016) Long Wu et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

(2016) Harry K Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

(2016) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Preventing painful age-related bone fractures

(2016) Michelle L Thompson et al.   Molecular Pain

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Postmenopausal Osteoporosis

(2016) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

(2016) Luc Chouinard et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction

(2016) Corinna Wehmeyer et al.   Science Translational Medicine

Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis

(2015) Christian Graeff et al.   BONE

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

(2015) Christopher P Recknor et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

(2015) Robert R. Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways

(2015) Wafa Bouaziz et al.   ARTHRITIS RESEARCH & THERAPY

Sclerostin Deficiency Is Linked to Altered Bone Composition

(2014) Norbert Hassler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Geographic and ethnic disparities in osteoporotic fractures

(2014) Jane A. Cauley et al.   Nature Reviews Endocrinology

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

(2013) E. Michael Lewiecki   Therapeutic Advances in Musculoskeletal Disease

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats

(2011) Xiaodong Li et al.   ENDOCRINOLOGY

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH